Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-25T17:09:10.763Z Has data issue: false hasContentIssue false

PP071 Health Technology Assessment In Bulgaria: A Review Of The First Fifteen Reports Assessed

Published online by Cambridge University Press:  12 January 2018

Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
INTRODUCTION:

In Bulgaria, the regulatory body sets for the first time legal requirements for Health Technology Assessment (HTA) in Law on Medicinal Products in Human Medicine (LMPHM) on 27 June 2015. The next essential step for HTA capacity building was the promulgation of Ordinance 9 / December 1, 2015 on the conditions and procedures for conducting health technology assessment by the Ministry of Health (1). In the beginning of 2016, the Main Price and Reimbursement Committee was set and launched a process for establishing the small working groups with the task of reviewing the first applicants reports of pharmaceuticals for inclusion in the Positive Drug List (PDL).

METHODS:

The objective of this study is to summarize the recommendations of the newly established HTA Committee in Bulgaria and to examine the characteristics of the technologies and the key considerations that led to those decisions. We systematically read all published by the Committee recommendations for 2016 and analyzed them under: type of recommendations (positive or negative for inclusion in PDL), population, specialization, type of service, type of justification and the impact on final conclusions.

RESULTS:

For the first year of its work the HTA Committee was able to assess fifteen technologies (pharmaceuticals) and only one received a negative recommendation (6 percent) from the working group. All the rest (n = 14; 94 percent) were recommended for funding. The final recommendation from the Main Price and Reimbursement Committee is available for four (27 percent) technologies – all positive for inclusion in PDL. All recommendations were connected with adults and in oncology (n = 4; 27 percent); heart diseases (n = 4; 27 percent); Chronic Obstructive Pulmonary Disease, COPD (n = 2; 13 percent); diabetes (n = 2; 13 percent); psoriasis (n = 2; 13 percent); Hepatitis C (n = 1; 7 percent). The only negative recommendation was justified due to lack of robust evidence, safety issues and credibility of HTA analysis (2).

CONCLUSIONS:

The information about the number of applications received from the Committee is not available and correct conclusions about the capability is not possible, but indirect circumstances, as the lack of well-trained HTA experts, certainly impede establishment of the small working groups and slow the assessment process (3). At this point it is clear that additional efforts are need to overcome the barriers and smooth adoption and implementation of HTA methods in Bulgaria.

Type
Poster Presentations
Copyright
Copyright © Cambridge University Press 2018 

References

REFERENCES:

1. Ministry of Health Bulgaria. Ordinance 9 / December 1, 2015 on the conditions and procedures for conducting Health Technology Assessment. (available in Bulgarian language). [web page]. Available from: https://www.mh.government.bg/media/filer_public/2015/12/11/naredba9-1-12-2015.pdf. (accessed January 12, 2017).Google Scholar
2. Raycheva, R. Health Technology Assessment Capacity Building and Institutionalization. Bulgarian perspectives. (Unpublished doctoral dissertation, 2016).Google Scholar
3. The National Center of Public Health and Analyses (NCPHA). [webpage]. Available from: http://ncpha.government.bg/index.php?option=com_content&view=category&layout=blog&id=373&Itemid=660&lang=en. (accessed on January 12, 2017).Google Scholar